<?xml version="1.0" encoding="utf-8"?>
<feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom">
  <title
    type="text">RCI Partners</title>
  <subtitle
    type="text">Contains the last 20 releases</subtitle>
  <id>uuid:be1f64eb-2faa-4ac9-b1f8-ce03d3a69cff;id=33011</id>
  <rights
    type="text">Copyright 2016, RCI Partners</rights>
  <updated>2016-09-16T12:00:00Z</updated>
  <author>
    <name>newsdesk@globenewswire.com (NewsDesk)</name>
    <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri>
    <email>newsdesk@globenewswire.com</email>
  </author>
  <link
    rel="alternate"
    href="https://www.globenewswire.com/atomfeed/organization/JkjMG8kD5WPBMPtQ5lVJ7A==" />
  <link
    rel="self"
    href="https://www.globenewswire.com/atomfeed/organization/JkjMG8kD5WPBMPtQ5lVJ7A==" />
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/09/16/950498/0/en/Retrotope-Announces-Phase-I-II-Clinical-Trial-Results-of-RT001-in-Treatment-of-Friedreich-s-Ataxia.html</id>
    <title
      type="text">Retrotope Announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich's Ataxia </title>
    <published>2016-09-16T12:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/09/16/950498/0/en/Retrotope-Announces-Phase-I-II-Clinical-Trial-Results-of-RT001-in-Treatment-of-Friedreich-s-Ataxia.html" />
    <content
      type="html"><![CDATA[<p><em><p>First-in-Human Trial Achieves Safety, Tolerability, and PK Goals, With Early Signals of Efficacy</p></em></p><p>LOS ALTOS, CA--(Marketwired - Sep 16, 2016) -  Dr. Theresa Zesiewicz, principal investigator in Retrotope's first-in-human clinical trial of RT001 in Friedreich's ataxia (FA), today presented early results from Retrotope's Phase I/II trial conducted at the University of South Florida Ataxia Research Center and the Collaborative NeuroSciences Network in Long Beach, CA. The trial, a randomized, double-blind, comparator controlled, two-dose study of RT001 in 18 FA patients for 28 days, met all of its primary safety, tolerability and pharmacokinetic (PK) goals. While biological activity was not a primary goal of the study, a number of clinically important activity measures were tested, found to be highly correlated to well-studied disease severity scales and showed multiple, unexpected, robust signals of drug effect at one or more doses.</p>]]></content>
    <dc:identifier>950498</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Retrotope</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2016/06/01/950496/0/en/US-FDA-Grants-Orphan-Drug-Designation-for-Retrotope-s-RT001-in-the-Treatment-of-Friedreich-s-Ataxia.html</id>
    <title
      type="text">US FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Friedreich's Ataxia </title>
    <published>2016-06-01T13:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2016/06/01/950496/0/en/US-FDA-Grants-Orphan-Drug-Designation-for-Retrotope-s-RT001-in-the-Treatment-of-Friedreich-s-Ataxia.html" />
    <content
      type="html"><![CDATA[<p><em><p>First-in-Human Clinical Trial for RT001 Is Now Fully Enrolled</p></em></p><p>LOS ALTOS, CA--(Marketwired - Jun 1, 2016) -  Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its stabilized fatty acid drug (RT001) for the treatment of Friedreich's ataxia (FA). This follows the recent announcement that RT001 was well tolerated with no serious adverse events or dose limiting toxicities in the first cohort of its Phase 1/2 clinical trial in FA patients.</p>]]></content>
    <dc:identifier>950496</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Retrotope</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/05/28/950494/0/en/Genelux-Appoints-George-Vandeman-and-Thomas-Zindrick-to-Board-of-Directors.html</id>
    <title
      type="text">Genelux Appoints George Vandeman and Thomas Zindrick to Board of Directors </title>
    <published>2014-05-28T16:00:41Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/05/28/950494/0/en/Genelux-Appoints-George-Vandeman-and-Thomas-Zindrick-to-Board-of-Directors.html" />
    <content
      type="html"><![CDATA[<p><em><p>Vandeman Becomes Vice Chairman and Fifth Independent Director on Nine-Member Board</p></em></p><p>SAN DIEGO, CA--(Marketwired - May 28, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced the appointment of Mr. George Vandeman, long-time Amgen executive, and Thomas Zindrick, newly appointed Genelux President and CEO of Genelux Corporation, to the company's Board of Directors. Mr. Vandeman has also been named Vice Chairman and is the Board's fifth independent Director. Together, the appointments expand the Genelux Corporation Board to nine members.</p>]]></content>
    <dc:identifier>950494</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>biotechnology pharmaceutical cancer finance</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/05/15/950492/0/en/Update-Genelux-Corporation-Announces-Former-Amgen-and-Abbott-Executives-to-Succeed-Founder-Aladar-A-Szalay-Ph-D-as-CEO-Chairman-of-the-Board.html</id>
    <title
      type="text">Update: Genelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board </title>
    <published>2014-05-15T17:17:54Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/05/15/950492/0/en/Update-Genelux-Corporation-Announces-Former-Amgen-and-Abbott-Executives-to-Succeed-Founder-Aladar-A-Szalay-Ph-D-as-CEO-Chairman-of-the-Board.html" />
    <content
      type="html"><![CDATA[<p><em><p>Appointment of Industry Experts Thomas Zindrick and James L. Tyree Ensures Seamless Transition</p></em></p><p>SAN DIEGO, CA--(Marketwired - May 15, 2014) - <strong>&#160;</strong>Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced that Aladar Szalay, PhD has chosen to retire from the positions of Chairman, President and CEO of Genelux for personal reasons. Dr. Szalay will continue to serve as chief scientific advisor to the CEO and remain on the company's board of directors as chairman emeritus. Effective May 2, 2014, pharmaceutical industry veteran and long-time Amgen executive, Mr. Thomas Zindrick will serve as president and CEO. Mr. James L. Tyree, formerly of Abbott will serve as chairman of the board.</p>]]></content>
    <dc:identifier>950492</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>biotechnology pharmaceutical cancer finance</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/05/12/950490/0/en/Genelux-Corporation-Announces-Former-Amgen-and-Abbott-Executives-to-Succeed-Founder-Aladar-A-Szalay-Ph-D-as-CEO-Chairman-of-the-Board.html</id>
    <title
      type="text">Genelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board </title>
    <published>2014-05-12T14:58:07Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/05/12/950490/0/en/Genelux-Corporation-Announces-Former-Amgen-and-Abbott-Executives-to-Succeed-Founder-Aladar-A-Szalay-Ph-D-as-CEO-Chairman-of-the-Board.html" />
    <content
      type="html"><![CDATA[<p><em><p>Appointment of Industry Experts Thomas Zindrick and James L. Tyree Ensures Seamless Transition</p></em></p><p>SAN DIEGO, CA--(Marketwired - May 12, 2014) -  Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced that Aladar Szalay, PhD has chosen to retire from the positions of Chairman, President and CEO of Genelux for personal reasons. Dr. Szalay will continue to serve as chief scientific advisor to the CEO and remain on the company's board of directors as chairman emeritus. Effective May 2, 2014, pharmaceutical industry veteran and long-time Amgen executive, Mr. Thomas Zindrick will serve as president and CEO. Mr. James L. Tyree, formerly of Abbott will serve as chairman of the board.</p>]]></content>
    <dc:identifier>950490</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>biotechnology pharmaceutical cancer finance</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/04/08/950488/0/en/Genelux-Corporation-CEO-Dr-Aladar-A-Szalay-to-Give-a-Keynote-Lecture-at-the-8th-International-Conference-on-Oncolytic-Virus-Therapeutics.html</id>
    <title
      type="text">Genelux Corporation CEO, Dr. Aladar A. Szalay, to Give a Keynote Lecture at the 8th International Conference on Oncolytic Virus Therapeutics </title>
    <published>2014-04-08T15:17:04Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/04/08/950488/0/en/Genelux-Corporation-CEO-Dr-Aladar-A-Szalay-to-Give-a-Keynote-Lecture-at-the-8th-International-Conference-on-Oncolytic-Virus-Therapeutics.html" />
    <content
      type="html"><![CDATA[<p><em><p>Genelux to Feature an Abstract on Diagnosing and Treating Cancer With Vaccinia Virus</p></em></p><p>SAN DIEGO, CA--(Marketwired - Apr 8, 2014) -  Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and diagnostics, today announced that its Founder and CEO, Dr. Aladar A. Szalay, a respected researcher and thought leader in the field of oncolytic virotherapy and immunotherapy, will give a keynote lecture at the 8<sup>th</sup> International Conference on Oncolytic Virus Therapeutics in Oxford, England from April 13 through 15, 2014. The annual meeting brings together the world's leading researchers and clinicians from the preeminent cancer centers, universities, and biotech and pharma companies investigating the use of oncolytic viruses for cancer diagnostics and therapeutics.&#160;Genelux will also present an abstract at the conference -- <em>Diagnosis and therapy of cancer with Vaccinia: from preclinical research to human clinical trials</em>.</p>]]></content>
    <dc:identifier>950488</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>biotechnology pharmaceutical cancer finance</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2014/02/11/950487/0/en/Genelux-Corporation-Appoints-John-D-Prunty-Chief-Financial-Officer.html</id>
    <title
      type="text">Genelux Corporation Appoints John D. Prunty Chief Financial Officer </title>
    <published>2014-02-11T13:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2014/02/11/950487/0/en/Genelux-Corporation-Appoints-John-D-Prunty-Chief-Financial-Officer.html" />
    <content
      type="html"><![CDATA[<p><em><p>Experienced Biotech Business and Finance Executive to Position Company for Commercialization and Growth</p></em></p><p>SAN DIEGO, CA--(Marketwired - Feb 11, 2014) -  Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, announced today that, after a lengthy executive search process, its Board of Directors has appointed John D. Prunty, Chief Financial Officer, effective February 10, 2014.&#160;</p>]]></content>
    <dc:identifier>950487</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>biotechnology pharmaceutical cancer finance</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/08/13/950486/0/en/FDA-Approves-Epaned-a-Liquid-Form-of-Enalapril-for-Children-and-Adults.html</id>
    <title
      type="text">FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults </title>
    <published>2013-08-13T17:59:11Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/08/13/950486/0/en/FDA-Approves-Epaned-a-Liquid-Form-of-Enalapril-for-Children-and-Adults.html" />
    <content
      type="html"><![CDATA[<p><em><p>Silvergate Pharmaceuticals Inc. Enables Consistent Dosing for Children</p></em></p><p>DENVER, CO--(Marketwired - Aug 13, 2013) - Silvergate Pharmaceuticals Inc. (<a href="http://www.silvergatepharma.com" title="www.silvergatepharma.com" rel="nofollow">www.silvergatepharma.com</a>), focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned&#8482; (enalapril maleate Powder for Oral Solution) to treat hypertension (high blood pressure) in people one month and older. Enalapril is one of the most commonly prescribed medicines in the United States to treat high blood pressure.&#160;</p>]]></content>
    <dc:identifier>950486</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Silvergate Pharmaceuticals, Inc.</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/06/27/950485/0/en/Genelux-Corporation-Appoints-Stefan-M-Manth-MD-as-President-CEO-Genelux-Europe.html</id>
    <title
      type="text">Genelux Corporation Appoints Stefan M. Manth, MD, as President &amp; CEO, Genelux Europe </title>
    <published>2013-06-27T12:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/06/27/950485/0/en/Genelux-Corporation-Appoints-Stefan-M-Manth-MD-as-President-CEO-Genelux-Europe.html" />
    <content
      type="html"><![CDATA[<p><em><p>Industry Veteran With More Than 25 Years Experience Will Lead Development and European Commercialization and Growth</p></em></p><p>SAN DIEGO, CA--(Marketwired - Jun 27, 2013) -  Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced its Board of Directors has appointed Stefan M. Manth, MD, to lead Genelux Europe, as President and Chief Executive Officer effective July 1, 2013, based in Basel, Switzerland.&#160;</p>]]></content>
    <dc:identifier>950485</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux Corporation</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <media:content
      medium="image"
      type="image/jpeg"
      width="600"
      url="http://media.marketwire.com/attachments/201306/167156_ManthPhoto.jpg">
      <media:text
        type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2013/06/27/950485/0/en/Genelux-Corporation-Appoints-Stefan-M-Manth-MD-as-President-CEO-Genelux-Europe.html">
    <img src="http://media.marketwire.com/attachments/201306/167156_ManthPhoto.jpg" width="600" align="left" border="0" alt="Photo" title="Genelux Corporation Appoints Stefan M. Manth, MD, as President &amp; CEO, Genelux Europe" />
  </a>
</p><br clear="all" />]]></media:text>
      <media:credit
        role="publishing company">GlobeNewswire Inc.</media:credit>
    </media:content>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/05/30/950483/0/en/Genelux-Corporation-Presents-Abstracts-at-2013-ASCO-Annual-Meeting-for-Clinical-Trials-of-GL-ONC1-Its-Oncolytic-Virus-Lead-Product-Candidate.html</id>
    <title
      type="text">Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate </title>
    <published>2013-05-30T11:30:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/05/30/950483/0/en/Genelux-Corporation-Presents-Abstracts-at-2013-ASCO-Annual-Meeting-for-Clinical-Trials-of-GL-ONC1-Its-Oncolytic-Virus-Lead-Product-Candidate.html" />
    <content
      type="html"><![CDATA[<p>SAN DIEGO, CA--(Marketwired - May 30, 2013) -  <a rel="nofollow" href="http://www.genelux.com/" title="Genelux Corporation">Genelux Corporation</a>, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today announced that it will present two posters at the American Society of Clinical Oncology&#160;(ASCO) 2013 Annual Meeting from May 31 - June 4 on its lead product candidate, GL-ONC1, an oncolytic (cancer-killing) viral therapy. The first poster, abstract 3098, "<em>Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresectable, chemotherapy-resistant peritoneal </em><em>carcinomatosis,</em>"<sup>1</sup> will be presented by the study's lead investigator, Ulrich Lauer, MD, Department of Gastroenterology &amp; Hepatology, Medical University Hospital, Tuebingen, Germany.&#160;</p>]]></content>
    <dc:identifier>950483</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux Corporation</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>cancer</dc:keyword>
    <dc:keyword>oncolytic virotherapy</dc:keyword>
    <dc:keyword>virotherapy</dc:keyword>
    <dc:keyword>carcinomatosis</dc:keyword>
    <dc:keyword>imaging</dc:keyword>
    <dc:keyword>ASCO</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/04/03/950481/0/en/Gastric-Cancer-Foundation-Founder-Joseph-Peter-Gallagher-Loses-Battle-With-Stomach-Cancer.html</id>
    <title
      type="text">Gastric Cancer Foundation Founder, Joseph Peter Gallagher, Loses Battle With Stomach Cancer </title>
    <published>2013-04-03T15:33:11Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/04/03/950481/0/en/Gastric-Cancer-Foundation-Founder-Joseph-Peter-Gallagher-Loses-Battle-With-Stomach-Cancer.html" />
    <content
      type="html"><![CDATA[<p>SAN CARLOS, CA--(Marketwired - Apr 3, 2013) -  Joseph Peter (J.P.) Gallagher, passionate advocate of finding a cure for stomach cancer, passed away on February 26 after surviving stomach cancer for five and a half years. He was 43.</p>]]></content>
    <dc:identifier>950481</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Gastric Cancer Foundation</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>gastric cancer</dc:keyword>
    <dc:keyword>stomach cancer</dc:keyword>
    <dc:keyword>HER-2</dc:keyword>
    <dc:keyword>FGFR2</dc:keyword>
    <dc:keyword>T-DM1</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/03/26/950479/0/en/Sir-Ken-Robinson-to-Provide-Keynote-Address-for-Parents-Education-Network-Education-Revolution-2013-Event-at-AT-T-Park.html</id>
    <title
      type="text">Sir Ken Robinson to Provide Keynote Address for Parents Education Network Education Revolution 2013 Event at AT&amp;T Park </title>
    <published>2013-03-26T12:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/03/26/950479/0/en/Sir-Ken-Robinson-to-Provide-Keynote-Address-for-Parents-Education-Network-Education-Revolution-2013-Event-at-AT-T-Park.html" />
    <content
      type="html"><![CDATA[<p><em><p>"Unleash Every Child's Potential" Is Theme of Inspirational Day for Parents, Teachers and Students</p></em></p><p>SAN FRANCISCO, CA--(Marketwire - Mar 26, 2013) - <a rel="nofollow" href="http://parentseducationnetwork.org/" title="Parents Education Network (PEN)">Parents Education Network (PEN)</a> today announced that Sir Ken Robinson, TED speaker, celebrated author and internationally recognized leader in the development of education, creativity and innovation, will provide the keynote address for the organization's annual event, <a rel="nofollow" href="http://www.edrevsf.org/" title=""><em>EdRev 2013, Unleash Every Child's Potential</em></a> (Education Revolution) on Saturday, April 13. Now in its fifth year, EdRev offers a special day dedicated to understanding each child's individuality in learning as the basis for creating new educational environments.</p>]]></content>
    <dc:identifier>950479</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Parents Education Network</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>education system</dc:keyword>
    <dc:keyword>learning disabilities</dc:keyword>
    <dc:keyword>ADHD</dc:keyword>
    <dc:keyword>dyslexia</dc:keyword>
    <dc:keyword>Sir Ken Robinson</dc:keyword>
    <dc:keyword>education overhaul</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/02/11/950510/0/en/Virus-Engineered-to-Express-Melanin-Offers-New-Possibilities-to-Diagnose-and-Treat-Solid-Tumor-Cancers.html</id>
    <title
      type="text">Virus Engineered to Express Melanin Offers New Possibilities to Diagnose and Treat Solid Tumor Cancers </title>
    <published>2013-02-11T20:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/02/11/950510/0/en/Virus-Engineered-to-Express-Melanin-Offers-New-Possibilities-to-Diagnose-and-Treat-Solid-Tumor-Cancers.html" />
    <content
      type="html"><![CDATA[<p><em><p>New Approach for Deep Tissue Imaging of Tumors and Treating Cancer With Thermotherapy Published in PNAS</p></em></p><p>SAN DIEGO, CA--(Marketwire - Feb 11, 2013) - In a study released today in <em>Proceedings of the National Academy of Sciences </em>(PNAS), entitled "Vaccinia virus mediated melanin production allows MR and optoacoustic deep tissue imaging and laser induced thermotherapy of cancer," scientists combined the natural imaging potential of melanin with recombinant Vaccinia viruses' ability to selectively enter and replicate within tumor cells. Melanins, dark pigments found in most organisms, are produced in certain types of cancers, such as melanoma, causing tissues to appear very bright in Magnetic Resonance Imaging (MRI).&#160;Significantly, the approach achieved sufficient concentrations of melanin in tumor cells to enable enhanced MRI and optoacoustic imaging (using sound and light waves to detect masses), as well as thermotherapy (laser-induced thermal lysis) of melanin-producing tumor cells.</p>]]></content>
    <dc:identifier>950510</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2013/02/06/950509/0/en/First-Patient-Treated-in-Genelux-Phase-I-Trial-With-GL-ONC1-at-Memorial-Sloan-Kettering-Cancer-Center.html</id>
    <title
      type="text">First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer Center </title>
    <published>2013-02-06T13:34:52Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2013/02/06/950509/0/en/First-Patient-Treated-in-Genelux-Phase-I-Trial-With-GL-ONC1-at-Memorial-Sloan-Kettering-Cancer-Center.html" />
    <content
      type="html"><![CDATA[<p><em><p>Study to Include Cancer Patients With Malignant Mesothelioma and Malignant Pleural Effusions From Other Primary Tumors</p></em></p><p>SAN DIEGO, CA--(Marketwire - Feb 6, 2013) -  Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and companion diagnostics, today announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York treated the first patient in a Phase I clinical trial of GL-ONC1 in people with malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers.<sup>1</sup> The safety and dose-escalation study will, for the first time, evaluate GL-ONC1 administered through the lung cavity (intra-pleurally) as a single agent therapy. Patients enrolled in the trial may have one of a number of possible cancer types such as malignant pleural mesothelioma or non-small cell lung cancer (NSCLC). Dr. Valerie W. Rusch, one of the world's leading thoracic surgeons and experts in mesothelioma, serves as Principal Investigator of the MSKCC-sponsored clinical trial.</p>]]></content>
    <dc:identifier>950509</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2012/11/01/950507/0/en/Genelux-Corporation-Announces-Early-Results-of-a-Phase-I-II-Clinical-Trial-of-Virotherapeutic-GL-ONC1-in-Advanced-Peritoneal-Cavity-Cancers.html</id>
    <title
      type="text">Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers </title>
    <published>2012-11-01T12:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2012/11/01/950507/0/en/Genelux-Corporation-Announces-Early-Results-of-a-Phase-I-II-Clinical-Trial-of-Virotherapeutic-GL-ONC1-in-Advanced-Peritoneal-Cavity-Cancers.html" />
    <content
      type="html"><![CDATA[<p><em><p>Early Evidence of Efficient Virotherapeutic Replication and Cancer Cell Lysis in GL-ONC1 Treated Patients</p></em></p><p>SAN DIEGO, CA--(Marketwire - Nov 1, 2012) -  Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics, announced early results of the first patient cohort treated in a Phase I/II clinical trial with GL-ONC1, its leading virotherapeutic product candidate, in patients with advanced peritoneal cavity cancers. As presented at the <em>8</em><em><sup>th</sup></em> <em>World Congress on Peritoneal Surface Malignancies</em> in Berlin, Germany, GL-ONC1 was found to be clinically well tolerated when applied directly into the peritoneal cavity. Further results also directly display profound infection and lysis (cell rupture resulting in cancer cell death) of malignant cells being present in the peritoneal fluid of these GL-ONC1 treated cancer patients.</p>]]></content>
    <dc:identifier>950507</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux Corporation</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2012/06/28/950505/0/en/Genelux-Corporation-Announces-Ground-Breaking-Clinical-Study-Evaluating-Oncolytic-Vaccinia-Virus-in-Canine-Cancer-Patients.html</id>
    <title
      type="text">Genelux Corporation Announces Ground-Breaking Clinical Study Evaluating Oncolytic Vaccinia Virus in Canine Cancer Patients </title>
    <published>2012-06-28T15:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2012/06/28/950505/0/en/Genelux-Corporation-Announces-Ground-Breaking-Clinical-Study-Evaluating-Oncolytic-Vaccinia-Virus-in-Canine-Cancer-Patients.html" />
    <content
      type="html"><![CDATA[<p><em><p>Renowned Veterinary Oncologist Gregory K. Ogilvie, DVM, to Lead Clinical Study</p></em></p><p>SAN DIEGO, CA--(Marketwire - Jun 28, 2012) -  Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagnostics for cancer, today announced the start of a ground-breaking clinical study involving the oncolytic vaccinia virus V-VET1 in canine cancer patients with various measurable malignancies. Although oncolytic viruses are being more extensively evaluated in humans, this study is the first of its kind ever-reported in dogs, and will evaluate the safety, dosing and efficacy of V-VET1, a veterinary-use, intravenously delivered oncolytic vaccinia virus. </p>]]></content>
    <dc:identifier>950505</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux Corporation</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
    <dc:keyword>canine cancer</dc:keyword>
    <dc:keyword>dogs with cancer</dc:keyword>
    <dc:keyword>comparitive oncology</dc:keyword>
    <dc:keyword>oncolytic virotherapy</dc:keyword>
    <dc:keyword>companion animals</dc:keyword>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2012/06/14/950503/0/en/Genelux-Corporation-Announces-First-Patient-Dosed-in-Phase-I-Combination-Clinical-Trial-of-GL-ONC1.html</id>
    <title
      type="text">Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1 </title>
    <published>2012-06-14T12:00:00Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2012/06/14/950503/0/en/Genelux-Corporation-Announces-First-Patient-Dosed-in-Phase-I-Combination-Clinical-Trial-of-GL-ONC1.html" />
    <content
      type="html"><![CDATA[<p><em><p>Investigational Medicine for Advanced Head & Neck Cancer to Be Studied in Combination With Chemoradiotherapy</p></em></p><p>SAN DIEGO, CA--(Marketwire - Jun 14, 2012) -  Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagnostics for cancer, today announced that the first patient has been dosed in a Phase I clinical trial of GL-ONC1 combined with chemoradiotherapy in patients with locoregionally advanced head and neck cancers. The study will evaluate whether GL-ONC1, administered intravenously as a combination therapy with cisplatin and radiotherapy (standard of care), may be safely given to patients with primary, non-metastatic disease, who have not undergone prior therapy or surgical interventions.</p>]]></content>
    <dc:identifier>950503</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2012/05/31/950501/0/en/Genelux-Corporation-Announces-Treatment-of-First-Patient-in-Phase-I-II-Clinical-Trial-of-GL-ONC1-in-Advanced-Peritoneal-Cavity-Cancers.html</id>
    <title
      type="text">Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers </title>
    <published>2012-05-31T13:15:17Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2012/05/31/950501/0/en/Genelux-Corporation-Announces-Treatment-of-First-Patient-in-Phase-I-II-Clinical-Trial-of-GL-ONC1-in-Advanced-Peritoneal-Cavity-Cancers.html" />
    <content
      type="html"><![CDATA[<p><em><p>Study Marks First Time Cancer Patients Are Treated With Oncolytic Vaccinia Virus in Germany</p></em></p><p>SAN DIEGO, CA--(Marketwire - May 31, 2012) -  Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today announced that the first patient was treated on April 30, 2012 in a Phase I/II clinical trial of GL-ONC1 in patients with advanced peritoneal cavity cancers. The safety and dose-escalation study will evaluate GL-ONC1 administered intra-peritoneally as a single agent therapy, and will include a number of possible of cancer types -- potentially gastric, colon, liver, kidney, ovarian and pancreatic cancer, among others. Importantly, this is the first time that a vaccinia-based oncolytic viral therapy was administered to a human cancer patient in Germany. </p>]]></content>
    <dc:identifier>950501</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
  <entry>
    <id>https://www.globenewswire.com/news-release/2012/05/30/950500/0/en/Genelux-Corporation-Announces-Phase-I-Data-Presentation-at-2012-ASCO-Annual-Meeting-of-GL-ONC1-Its-Oncolytic-Virus-Lead-Product-Candidate.html</id>
    <title
      type="text">Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate </title>
    <published>2012-05-30T17:17:51Z</published>
    <updated>2024-11-24T05:06:34Z</updated>
    <link
      rel="alternate"
      href="https://www.globenewswire.com/news-release/2012/05/30/950500/0/en/Genelux-Corporation-Announces-Phase-I-Data-Presentation-at-2012-ASCO-Annual-Meeting-of-GL-ONC1-Its-Oncolytic-Virus-Lead-Product-Candidate.html" />
    <content
      type="html"><![CDATA[<p>SAN DIEGO, CA--(Marketwire - May 30, 2012) -  Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today announced that data related to the company's oncolytic viral therapy, GL-ONC1, will be presented in a poster session at the 2012 American Society of Clinical Oncology (ASCO) annual meeting from June 1<sup>st</sup> to June 5<sup>th</sup> in Chicago, IL. The data relate to the completed Phase 1 clinical trial of GL-ONC1 administered to patients with advanced solid tumors and show preliminary evidence of anti-tumor activity with Stable Disease observed in 33% of patients (9 of 27) across a range of cancers.</p>]]></content>
    <dc:identifier>950500</dc:identifier>
    <dc:language>en</dc:language>
    <dc:publisher>GlobeNewswire Inc.</dc:publisher>
    <dc:contributor>Genelux</dc:contributor>
    <dc:modified>Sat, 16 Sep 2017 02:01 GMT</dc:modified>
  </entry>
</feed>